Skip to main content
Clinical Trials/NCT02657408
NCT02657408
Completed
Phase 1

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase I Trial in Healthy Male Current Smoker Subjects to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response and Safety of 4 Weeks Oral Administration of BI 1026706

Boehringer Ingelheim1 site in 1 country57 target enrollmentMarch 11, 2016
ConditionsHealthy
InterventionsBI 1026706Placebo

Overview

Phase
Phase 1
Intervention
BI 1026706
Conditions
Healthy
Sponsor
Boehringer Ingelheim
Enrollment
57
Locations
1
Primary Endpoint
Total Cell Count of Neutrophils in Bronchoalveolar Lavage (BAL) Fluid After 24 Hours of the Segmental Lipopolysaccharide (LPS) Challenge
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The primary and secondary objectives of the current study are the assessments of anti-inflammatory pharmacodynamic effects on segmental endotoxin induced inflammatory response after 4 weeks treatment with BI 1026706.

Registry
clinicaltrials.gov
Start Date
March 11, 2016
End Date
March 13, 2017
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

BI 1026706

Intervention: BI 1026706

Placebo

Intervention: Placebo

Outcomes

Primary Outcomes

Total Cell Count of Neutrophils in Bronchoalveolar Lavage (BAL) Fluid After 24 Hours of the Segmental Lipopolysaccharide (LPS) Challenge

Time Frame: Day 29

Total cell count of neutrophils in Bronchoalveolar Lavage (BAL) fluid after 24 hours of the segmental Lipopolysaccharide (LPS) challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the Least Square (LS) means obtained by fitting an Analysis of variance (ANOVA) model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method.

Secondary Outcomes

  • Differential Cell Count of Eosinophil in BAL Fluid 24 h After Segmental LPS Challenge.(Day 29)
  • Total Cell Count of Macrophage+Monocyte in BAL Fluid After 24 Hours of the Segmental LPS Challenge(Day 29)
  • Differential Cell Count of Neutrophils in BAL Fluid 24 h After Segmental LPS Challenge.(Day 29)
  • Total Cell Count of Monocyte in BAL Fluid After 24 Hours of the Segmental LPS Challenge(Day 29)
  • Total Cell Count of Eosinophil in BAL Fluid After 24 Hours of the Segmental LPS Challenge(Day 29)
  • Differential Cell Count of Monocyte in BAL Fluid 24 h After Segmental LPS Challenge.(Day 29)
  • Total Cell Count of Lymphocyte in BAL After 24 Hours of the Segmental LPS Challenge(Day 29)
  • Differential Cell Count of Lymphocyte in BAL Fluid 24 h After Segmental LPS Challenge.(Day 29)
  • Differential Cell Count of Macrophage+Monocyte in BAL Fluid 24 h After Segmental LPS Challenge.(Day 29)

Study Sites (1)

Loading locations...

Similar Trials